Leerink Partnrs Analysts Raise Earnings Estimates for BBIO

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Leerink Partnrs upped their Q1 2025 earnings per share estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Wednesday, February 26th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($0.72) for the quarter, up from their previous estimate of ($0.73). The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma's Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.24) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at $0.61 EPS, FY2028 earnings at $3.28 EPS and FY2029 earnings at $4.88 EPS.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The firm had revenue of $5.88 million for the quarter, compared to analyst estimates of $4.04 million.

BBIO has been the subject of a number of other research reports. HC Wainwright reissued a "buy" rating and issued a $49.00 target price on shares of BridgeBio Pharma in a report on Thursday, February 13th. Bank of America boosted their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, November 25th. Scotiabank upped their target price on BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Friday, February 21st. Evercore ISI lifted their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a report on Monday, December 23rd. Finally, Citigroup increased their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a report on Friday, February 21st. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $51.67.

Remove Ads

BridgeBio Pharma Stock Up 1.6 %

NASDAQ:BBIO traded up $0.53 during midday trading on Friday, reaching $33.54. The stock had a trading volume of 2,988,913 shares, compared to its average volume of 3,169,507. The stock has a market cap of $6.38 billion, a P/E ratio of -11.77 and a beta of 1.07. The firm has a fifty day simple moving average of $32.79 and a two-hundred day simple moving average of $28.40. BridgeBio Pharma has a 12-month low of $21.62 and a 12-month high of $39.47.

Hedge Funds Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of BridgeBio Pharma by 6.2% in the fourth quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company's stock valued at $413,738,000 after acquiring an additional 879,059 shares during the period. Janus Henderson Group PLC increased its position in shares of BridgeBio Pharma by 1.9% during the 4th quarter. Janus Henderson Group PLC now owns 4,907,533 shares of the company's stock worth $134,672,000 after purchasing an additional 89,521 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of BridgeBio Pharma by 140.1% during the fourth quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company's stock worth $115,111,000 after buying an additional 2,448,000 shares in the last quarter. Frazier Life Sciences Management L.P. raised its position in BridgeBio Pharma by 1.1% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company's stock valued at $104,285,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Capital Research Global Investors raised its holdings in shares of BridgeBio Pharma by 34.9% in the fourth quarter. Capital Research Global Investors now owns 3,526,747 shares of the company's stock valued at $96,774,000 after buying an additional 912,439 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company's stock.

Insider Buying and Selling

In related news, CEO Neil Kumar sold 326,932 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the sale, the chief executive officer now directly owns 5,371,515 shares in the company, valued at approximately $194,932,279.35. This trade represents a 5.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Brian C. Stephenson sold 8,500 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $33.19, for a total value of $282,115.00. Following the sale, the chief financial officer now owns 102,464 shares of the company's stock, valued at approximately $3,400,780.16. This represents a 7.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,579,739 shares of company stock valued at $125,411,901 over the last three months. Company insiders own 24.66% of the company's stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.